Stealth BioTherapeutics Stock Forecast, Price & News

Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

Is Stealth BioTherapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Stealth BioTherapeutics stock.
View analyst ratings for Stealth BioTherapeutics or view top-rated stocks.

How has Stealth BioTherapeutics' stock been impacted by Coronavirus?

Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MITO stock has decreased by 52.2% and is now trading at $0.76.
View which stocks have been most impacted by COVID-19.

Are investors shorting Stealth BioTherapeutics?

Stealth BioTherapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 60,000 shares, an increase of 57.9% from the December 15th total of 38,000 shares. Based on an average daily trading volume, of 153,000 shares, the days-to-cover ratio is currently 0.4 days.
View Stealth BioTherapeutics' Short Interest.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, April 5th 2022.
View our earnings forecast for Stealth BioTherapeutics.

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.02).
View Stealth BioTherapeutics' earnings history.

What price target have analysts set for MITO?

2 Wall Street analysts have issued 1 year target prices for Stealth BioTherapeutics' stock. Their forecasts range from $3.00 to $4.00. On average, they expect Stealth BioTherapeutics' share price to reach $3.50 in the next year. This suggests a possible upside of 360.5% from the stock's current price.
View analysts' price targets for Stealth BioTherapeutics or view top-rated stocks among Wall Street analysts.

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:

• Irene P. McCarthy, Chief Executive Officer & Director
• Robert J. Weiskopf, Chief Financial Officer
• James R. Carr, Chief Clinical Development Officer
• Martin P. Redmon, Chief Research & Development Officer
• Brian D. Blakey, Chief Business Officer

Who are some of Stealth BioTherapeutics' key competitors?

Some companies that are related to Stealth BioTherapeutics include Frequency Therapeutics (FREQ), Anebulo Pharmaceuticals (ANEB), TFF Pharmaceuticals (TFFP), CorMedix (CRMD), PDS Biotechnology (PDSB), Humanigen (HGEN), Inozyme Pharma (INZY), Atossa Therapeutics (ATOS), UroGen Pharma (URGN), PLx Pharma (PLXP), Clene (CLNN), Spectrum Pharmaceuticals (SPPI), Larimar Therapeutics (LRMR), InflaRx (IFRX) and DURECT (DRRX).
View all of MITO's competitors.

What other stocks do shareholders of Stealth BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB), Soleno Therapeutics (SLNO) and Arbutus Biopharma (ABUS).

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $0.76.

How much money does Stealth BioTherapeutics make?

Stealth BioTherapeutics has a market capitalization of $43.76 million and generates $21.09 million in revenue each year. The company earns $-57.46 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Stealth BioTherapeutics have?

Stealth BioTherapeutics employs 2,020 workers across the globe.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is www.stealthbt.com.

Where are Stealth BioTherapeutics' headquarters?

Stealth BioTherapeutics is headquartered at 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected].